Journal
EXPERT OPINION ON DRUG SAFETY
Volume 7, Issue 3, Pages 259-270Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14740338.7.3.259
Keywords
breast cancer; chemoprevention; estrogen receptor; raloxifene; SERMS
Categories
Ask authors/readers for more resources
Background: Raloxifene is a benzothiophene, selective estrogen receptor modulator with estrogen-agonist effects in the skeleton and the cardiovascular system but estrogen-antagonist effects in the uterus and the mammary gland. This compound was first approved in different countries for the prevention and treatment of osteoporosis. Objective/methods: We performed a literature search to review available preclinical and clinical data that has led to the recent FDA approval of raloxifene as a chemopreventive agent for breast cancer in postmenopausal women. Results/conclusions: Different placebo-controlled trials indicated that raloxifene is effective in reducing invasive breast cancer risk in postmenopausal women. In a recent comparative study, a similar efficacy between raloxifene and tamoxifen for breast cancer prevention was demonstrated, but raloxifene showed a more favorable safety profile.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available